Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Brucella dissociation is essential for macrophage egress and bacterial dissemination.

Pei J, Kahl-McDonagh M, Ficht TA.

Front Cell Infect Microbiol. 2014 Mar 5;4:23. doi: 10.3389/fcimb.2014.00023. eCollection 2014.

2.

Extended safety and efficacy studies of the attenuated Brucella vaccine candidates 16 M(Delta)vjbR and S19(Delta)vjbR in the immunocompromised IRF-1-/- mouse model.

Arenas-Gamboa AM, Rice-Ficht AC, Fan Y, Kahl-McDonagh MM, Ficht TA.

Clin Vaccine Immunol. 2012 Feb;19(2):249-60. doi: 10.1128/CVI.05321-11. Epub 2011 Dec 14.

3.

Protective efficacy and safety of Brucella melitensis 16MΔmucR against intraperitoneal and aerosol challenge in BALB/c mice.

Arenas-Gamboa AM, Rice-Ficht AC, Kahl-McDonagh MM, Ficht TA.

Infect Immun. 2011 Sep;79(9):3653-8. doi: 10.1128/IAI.05330-11. Epub 2011 Jun 27. Erratum in: Infect Immun. 2011 Dec;79(12):5040.

4.

In vitro mutagenesis of Brucella species.

Ficht TA, Pei J, Kahl-McDonagh M.

Methods Mol Biol. 2010;634:15-35. doi: 10.1007/978-1-60761-652-8_2.

PMID:
20676973
5.

Polymeric particles in vaccine delivery.

Rice-Ficht AC, Arenas-Gamboa AM, Kahl-McDonagh MM, Ficht TA.

Curr Opin Microbiol. 2010 Feb;13(1):106-12. doi: 10.1016/j.mib.2009.12.001. Epub 2010 Jan 14. Review.

PMID:
20079678
6.

Oral vaccination with microencapsuled strain 19 vaccine confers enhanced protection against Brucella abortus strain 2308 challenge in red deer (Cervus elaphus elaphus).

Arenas-Gamboa AM, Ficht TA, Davis DS, Elzer PH, Kahl-McDonagh M, Wong-Gonzalez A, Rice-Ficht AC.

J Wildl Dis. 2009 Oct;45(4):1021-9.

PMID:
19901378
7.

Brucellosis: the case for live, attenuated vaccines.

Ficht TA, Kahl-McDonagh MM, Arenas-Gamboa AM, Rice-Ficht AC.

Vaccine. 2009 Nov 5;27 Suppl 4:D40-3. doi: 10.1016/j.vaccine.2009.08.058. Review.

8.

The Brucella abortus S19 DeltavjbR live vaccine candidate is safer than S19 and confers protection against wild-type challenge in BALB/c mice when delivered in a sustained-release vehicle.

Arenas-Gamboa AM, Ficht TA, Kahl-McDonagh MM, Gomez G, Rice-Ficht AC.

Infect Immun. 2009 Feb;77(2):877-84. doi: 10.1128/IAI.01017-08. Epub 2008 Dec 1.

9.

Immunization with a single dose of a microencapsulated Brucella melitensis mutant enhances protection against wild-type challenge.

Arenas-Gamboa AM, Ficht TA, Kahl-McDonagh MM, Rice-Ficht AC.

Infect Immun. 2008 Jun;76(6):2448-55. doi: 10.1128/IAI.00767-07. Epub 2008 Mar 24.

10.

VirB12 is a serological marker of Brucella infection in experimental and natural hosts.

Rolán HG, den Hartigh AB, Kahl-McDonagh M, Ficht T, Adams LG, Tsolis RM.

Clin Vaccine Immunol. 2008 Feb;15(2):208-14. Epub 2007 Dec 12.

11.

Cytotoxicity in macrophages infected with rough Brucella mutants is type IV secretion system dependent.

Pei J, Wu Q, Kahl-McDonagh M, Ficht TA.

Infect Immun. 2008 Jan;76(1):30-7. Epub 2007 Oct 15.

12.

Aerosol infection of BALB/c mice with Brucella melitensis and Brucella abortus and protective efficacy against aerosol challenge.

Kahl-McDonagh MM, Arenas-Gamboa AM, Ficht TA.

Infect Immun. 2007 Oct;75(10):4923-32. Epub 2007 Jul 30.

14.

Evaluation of novel Brucella melitensis unmarked deletion mutants for safety and efficacy in the goat model of brucellosis.

Kahl-McDonagh MM, Elzer PH, Hagius SD, Walker JV, Perry QL, Seabury CM, den Hartigh AB, Tsolis RM, Adams LG, Davis DS, Ficht TA.

Vaccine. 2006 Jun 12;24(24):5169-77. Epub 2006 Apr 27.

PMID:
16697090

Supplemental Content

Loading ...
Support Center